Mankind Pharma Delivers Robust Sales in Q1 FY26; Stock Moves Higher

Mankind Pharma shares advanced 2.19% in early trade on Friday, reaching ₹2,623.40 as of 09:36 AM. The stock showed upward momentum, contributing to gains in the Nifty Midcap 150 index, backed by a consistent financial performance and recent corporate activity. 💼 Quarterly Performance: In the quarter ending June 2025, Mankind Pharma reported: Revenue of ₹3,570.35 Cr (↑ from ₹2,893.42 Cr YoY) Net Profit of ₹441.45 Cr (↓ from ₹539.16 Cr YoY) EPS at ₹10.62 (vs ₹13.39 YoY) Despite a dip in net profit YoY, topline growth and margin stability reflected operational strength. 📊 Yearly Financial Highlights (Consolidated): FY2025 Revenue: ₹12,207.44 Cr (up 96.4% from FY2021) FY2025 Net Profit: ₹1,994.35 Cr (up from ₹1,281.36 Cr in FY2021) EPS grew to ₹49.28; Book Value rose to ₹347.37 The company also witnessed notable growth in standalone sales, EBIT, and assets, although debt levels increased (D/E rose to 0.59 in FY25 from 0.02 in FY23), partly due to aggressive investment and expansion. 🧾 Key Ratios (FY2025): ROE: 13.89% Gross Margin: 32.17% Net Profit Margin: 20.48% Interest Coverage Ratio: 8.22 Debt to Equity: 0.50 3-Year CAGR (Sales): 14.40% P/E: 50.35x 🏢 Corporate Updates: Dividend Tax Communication released on July 31, 2025 Care Ratings Monitoring Report for Q1 FY26 submitted CMO Resignation: Dr. Sanjay Koul stepped down, effective August 1, 2025